Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05444972 · ClinicalTrials.gov registry record
A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review
A clinical trial, sponsored by AbbVie.
- Completed
- Registry status
- 998
- Enrollment target
NCT05444972 is a clinical trial that has completed, run by AbbVie. The registered enrollment target is 998 participants.
The verdict
NCT05444972 has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- 998 participants
- Enrollment target
Study Summary
Myelofibrosis (MF) is a rare blood cancer, characterized by extensive fibrosis (scarring) of the bone marrow. It is one of a group of cancers known as myeloproliferative neoplasms (MPNs) in which bone marrow cells that produce blood cells develop and function abnormally. This study will evaluate treatment patterns, treatment outcomes, healthcare resource utilization in adult participants with Myelofibrosis. Data from approximately 1000 participants will be collected. No participants will be enrolled in this study. Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the observation period is up to 156 weeks. There is no additional burden for participants in this trial. All visits must be completed prior to data extraction and participants will be followed for up to 156 weeks.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 998 participants |
| Start Date | 2022-08-23 |
| Est. Completion | 2023-11-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05444972
The ClinicalTrials.gov registry entry for NCT05444972 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 998 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05444972 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05444972 about?
NCT05444972 is a clinical study titled "A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review". Myelofibrosis (MF) is a rare blood cancer, characterized by extensive fibrosis (scarring) of the bone marrow. It is one of a group of cancers known as myeloproliferative neoplasms (MPNs) in which bone marrow cells that produce blood cells develop and function abnormally. This study will evaluate tre...
What is the current status of trial NCT05444972?
This trial is currently completed. The enrollment target is 998 participants. The study started on 2022-08-23. Estimated completion is 2023-11-14.
Who is sponsoring clinical trial NCT05444972?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.